186 related articles for article (PubMed ID: 8603447)
1. Effects of combined and sequential treatment with tamoxifen and the aromatase inhibitor vorozole on 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma in the rat.
Van Ginckel R; Janssens B; Callens M; Goeminne N; Wouters L; De Coster R
Cancer Chemother Pharmacol; 1996; 38(1):21-8. PubMed ID: 8603447
[TBL] [Abstract][Full Text] [Related]
2. Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors.
De Coster R; Van Ginckel RF; Callens MJ; Goeminne NK; Janssens BL
Cancer Res; 1992 Mar; 52(5):1240-4. PubMed ID: 1737385
[TBL] [Abstract][Full Text] [Related]
3. A novel aromatase inhibitor, vorozole, shows antitumor activity and a decrease of tissue insulin-like growth factor-I level in 7, 12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Sugamata N; Koibuchi Y; Iino Y; Morishita Y
Int J Oncol; 1999 Feb; 14(2):259-63. PubMed ID: 9917500
[TBL] [Abstract][Full Text] [Related]
4. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
Lu Q; Liu Y; Long BJ; Grigoryev D; Gimbel M; Brodie A
Breast Cancer Res Treat; 1999 Sep; 57(2):183-92. PubMed ID: 10598045
[TBL] [Abstract][Full Text] [Related]
5. The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens.
Brodie AH; Jelovac D; Long B
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):283-8. PubMed ID: 14623522
[TBL] [Abstract][Full Text] [Related]
6. Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model.
Lubet RA; Steele VE; DeCoster R; Bowden C; You M; Juliana MM; Eto I; Kelloff GJ; Grubbs CJ
Carcinogenesis; 1998 Aug; 19(8):1345-51. PubMed ID: 9744527
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer.
Harper-Wynne CL; Sacks NP; Shenton K; MacNeill FA; Sauven P; Laidlaw IJ; Rayter Z; Miall S; Howes A; Salter J; Hills MJ; Lowe FM; A'Hern R; Nasiri N; Doody D; Iqbal J; Dowsett M
J Clin Oncol; 2002 Feb; 20(4):1026-35. PubMed ID: 11844826
[TBL] [Abstract][Full Text] [Related]
8. Potent inhibitory effect of a new antiestrogen (RU 16117) on the growth of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Kelly PA; Asselin J; Caron MG; Labrie F; Raynaud JP
J Natl Cancer Inst; 1977 Mar; 58(3):623-8. PubMed ID: 402479
[TBL] [Abstract][Full Text] [Related]
9. Vorozole, a specific non-steroidal aromatase inhibitor.
Wouters W; Snoeck E; De Coster R
Breast Cancer Res Treat; 1994; 30(1):89-94. PubMed ID: 7726994
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of SEF19, a new nonsteroidal aromatase inhibitor, on 7,12-dimethylbenz[a]anthracene-induced mammary tumors in rats.
Iino Y; Karakida T; Sugamata N; Andoh T; Takei H; Takahashi M; Yaguchi S; Matsuno T; Takehara M; Sakato M; Kawashima S; Morishita Y
Anticancer Res; 1998; 18(1A):171-6. PubMed ID: 9568073
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of the novel anti-estrogen EM-800 and medroxyprogesterone acetate on estrone-stimulated growth of dimethylbenz[a]anthracene-induced mammary carcinoma in rats.
Luo S; Stojanovic M; Labrie C; Labrie F
Int J Cancer; 1997 Nov; 73(4):580-6. PubMed ID: 9389575
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of medroxyprogesterone acetate (MPA) and the pure antiestrogen EM-219 on estrone (E1)-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.
Li S; Lévesque C; Geng CS; Yan X; Labrie F
Breast Cancer Res Treat; 1995 May; 34(2):147-59. PubMed ID: 7647332
[TBL] [Abstract][Full Text] [Related]
13. Effect of CGS 16949A plus tamoxifen on induced mammary tumours in rats.
Tominaga T; Yoshida Y; Shimozuma K; Hayashi K; Kosaki G
Eur J Cancer; 1990; 26(5):600-3. PubMed ID: 2144748
[TBL] [Abstract][Full Text] [Related]
14. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative effect of the new aromatase inhibitor fadrozole on pre- and postmenopausal models of rat mammary tumor.
Tanaka M; Yano S; Hasegawa Y; Nakao K
Arzneimittelforschung; 1994 Jun; 44(6):774-8. PubMed ID: 8053980
[TBL] [Abstract][Full Text] [Related]
16. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Brodie A; Lu Q; Liu Y; Long B; Wang JP; Yue W
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):36-40. PubMed ID: 9556790
[TBL] [Abstract][Full Text] [Related]
17. The effects of aromatase inhibitors and antiestrogens in the nude mouse model.
Lu Q; Yue W; Wang J; Liu Y; Long B; Brodie A
Breast Cancer Res Treat; 1998 Jul; 50(1):63-71. PubMed ID: 9802621
[TBL] [Abstract][Full Text] [Related]
18. Prevention of DMBA-induced rat mammary carcinomas comparing leuprolide, oophorectomy, and tamoxifen.
Hollingsworth AB; Lerner MR; Lightfoot SA; Wilkerson KB; Hanas JS; McCay PB; Brackett DJ
Breast Cancer Res Treat; 1998 Jan; 47(1):63-70. PubMed ID: 9493977
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of the antitumor efficacy of the antiprogestin, onapristone, by combination with the antiestrogen, ICI 164384.
Nishino Y; Schneider MR; Michna H
J Cancer Res Clin Oncol; 1994; 120(5):298-302. PubMed ID: 8126059
[TBL] [Abstract][Full Text] [Related]
20. Combined effects of dehydroepiandrosterone and EM-800 on bone mass, serum lipids, and the development of dimethylbenz(A)anthracene-induced mammary carcinoma in the rat.
Luo S; Sourla A; Labrie C; Bélanger A; Labrie F
Endocrinology; 1997 Oct; 138(10):4435-44. PubMed ID: 9322961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]